CRIS Current Research Information System

VENTURI, CLAUDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.438
AS - Asia 3.024
EU - Europa 2.504
AF - Africa 197
SA - Sud America 192
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 9.363
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.390
VN - Vietnam 830
SG - Singapore 791
CN - Cina 735
GB - Regno Unito 642
IT - Italia 422
SE - Svezia 341
DE - Germania 321
HK - Hong Kong 209
FR - Francia 160
IN - India 142
BR - Brasile 133
RU - Federazione Russa 129
NL - Olanda 113
IE - Irlanda 84
ZA - Sudafrica 67
JP - Giappone 65
TG - Togo 58
EE - Estonia 51
CH - Svizzera 47
FI - Finlandia 44
UA - Ucraina 42
KR - Corea 38
JO - Giordania 35
BG - Bulgaria 31
NG - Nigeria 30
CA - Canada 29
PH - Filippine 27
AR - Argentina 26
BD - Bangladesh 26
CI - Costa d'Avorio 22
IR - Iran 20
IQ - Iraq 19
TH - Thailandia 19
BE - Belgio 17
PL - Polonia 13
MX - Messico 12
AT - Austria 10
TW - Taiwan 10
TR - Turchia 9
EC - Ecuador 8
LB - Libano 8
ES - Italia 7
GR - Grecia 7
VE - Venezuela 7
ID - Indonesia 6
SC - Seychelles 6
PE - Perù 5
PK - Pakistan 5
SA - Arabia Saudita 5
TN - Tunisia 5
UZ - Uzbekistan 5
AU - Australia 4
CL - Cile 4
MY - Malesia 4
PT - Portogallo 4
PY - Paraguay 4
QA - Qatar 4
RO - Romania 4
AE - Emirati Arabi Uniti 3
DK - Danimarca 3
KZ - Kazakistan 3
LT - Lituania 3
MA - Marocco 3
BO - Bolivia 2
CO - Colombia 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
EU - Europa 2
JM - Giamaica 2
LV - Lettonia 2
OM - Oman 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
CY - Cipro 1
EG - Egitto 1
ET - Etiopia 1
HN - Honduras 1
IL - Israele 1
KE - Kenya 1
KH - Cambogia 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
MT - Malta 1
RS - Serbia 1
SN - Senegal 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZW - Zimbabwe 1
Totale 9.363
Salva come PNG Salva come JPEG
Città #
Southend 597
Singapore 531
Ashburn 399
Chandler 357
Fairfield 258
San Jose 211
Hong Kong 198
Ho Chi Minh City 174
Beijing 161
Houston 159
Seattle 139
Woodbridge 139
Hanoi 135
Wilmington 135
Dong Ket 117
Princeton 116
Ann Arbor 110
Cambridge 87
Dublin 84
Santa Clara 82
Boardman 81
Bologna 81
New York 65
Lomé 58
Nanjing 56
Lauterbourg 55
Westminster 54
Tokyo 53
Padova 51
Los Angeles 46
Hefei 45
Medford 43
Bern 42
Amman 35
Frankfurt am Main 34
Helsinki 30
Sofia 30
Milan 29
Munich 29
Abeokuta 27
Redmond 27
Bremen 26
Hebei 26
Seoul 26
São Paulo 25
Buffalo 24
Jinan 24
Shenyang 24
Abidjan 22
Haiphong 22
Redondo Beach 22
Saint Petersburg 22
Berlin 21
Da Nang 21
San Diego 19
Jiaxing 18
Brussels 17
Dallas 16
Falls Church 16
Johannesburg 16
Redwood City 16
Nanchang 15
Changsha 14
Guangzhou 14
Orem 14
Tianjin 14
Turin 14
Nuremberg 13
Shanghai 13
Baghdad 12
Rome 12
Tehran 11
Atlanta 10
Council Bluffs 10
Florence 10
Mountain View 10
Turku 10
Zhengzhou 10
Falkenstein 9
Montreal 9
Norwalk 9
Paris 9
Phoenix 9
Toronto 8
Bangkok 7
Dearborn 7
Hải Dương 7
London 7
Ningbo 7
Warsaw 7
Amsterdam 6
Bengaluru 6
Brescia 6
Bến Tre 6
Can Tho 6
Chengdu 6
Chicago 6
Fuzhou 6
Hangzhou 6
Shijiazhuang 6
Totale 5.944
Salva come PNG Salva come JPEG
Nome #
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 283
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 244
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 234
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 227
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 222
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 214
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 212
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 209
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 207
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 192
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 188
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 183
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 183
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 181
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing 181
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 178
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 177
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 173
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 172
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 172
An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease 165
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 165
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 163
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 163
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 161
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 160
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 159
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 159
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 158
COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES 157
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 156
Evaluation of the Diasorin Q-Lamp technology for the molecular diagnosis of the philadelphia positive leukemias: an italian multicenter study 156
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. 156
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 155
One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study 153
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 152
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 150
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights 145
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 145
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 141
SEVERAL FUSION TRANSCRIPTS ARE DETECTED BY NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING APPROACH IN ADULT BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 141
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 141
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 141
Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome 140
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 140
Bcr-Abl kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the 2nd-generation TKI era 140
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse 139
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 138
Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) 136
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 129
Molecular characterization of TP53 mutations in B-acute lymphoblastic leukemia (B-ALL) reveals missense substitutions, aberrant exon-junctions and intron retention events 126
Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies 125
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia 123
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 122
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 117
SET-UP OF A MULTIPLEX PCR TO RAPIDLY DETECT IKZF1 (IKAROS) GENE BREAKPOINT DELETION IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 116
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement 108
You have accessClinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters 98
null 76
Totale 9.547
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.350
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.350
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021283 0 0 0 0 0 0 0 0 0 0 0 283
2021/20221.082 98 19 58 86 123 71 11 49 56 88 195 228
2022/20231.300 153 197 49 177 107 112 34 81 207 26 85 72
2023/2024347 11 60 21 36 21 88 14 29 23 15 10 19
2024/20251.227 48 186 124 105 123 44 101 30 22 150 53 241
2025/20262.884 244 188 221 154 347 140 261 107 805 252 94 71
Totale 9.547